I think Leronlimab may also be an easy pitch to insurance... Misiu might be able to elaborate on the medical mechanics... but my thought is that insurance is ok with paying for something that will improve overall health outcomes and limit co-morbidity of patients.

Leronlimab's safety profile and ease of adherence should greatly reduce any co-morbidities of cancer patients. In aggregate, the cost associated with cancer patients should decrease when taking Leronlimab.